Vessel normalization aims to correct the abnormal vasculature in the tumor to improve drug delivery and immune control. In this issue of Cell, Wang et al. identify an immune-excluding vasculature in small-cell lung cancer, where excessive vessel integrity drives immune desertification, and propose “reverse normalization” to restore immune access and overcome immunotherapy resistance.